Phase 3 MagnetisMM-5 Trial Results: Elrexfio (elranatamab) Significantly and Clinically Improves Progression-Free Survival in RRMM Patients Who Received at Least One Prior Line of Treatment (https://www.myeloma.org/news-events/multiple-myeloma-news/magnetismm-5-elranatamab-improves-pfs-rrmm)